Intralymphatic Allergen Immunotherapy (ILIT) in grass pollen allergy: a randomized controlled trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522376-82-00

Enrollment

Registered

2025-10-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic asthma, allergic diseases (allergic rhinosinusitis, allergy to Hymenoptera venoms)

Brief summary

1. Symptom scores (SS) (primary endpoint), ranging from 0 to 18 points, with 3 nasal and 3 ocular symptoms (runny nose, blocked nose, sneezing, red eyes, itchy eyes and watery eyes), each of which scored from 0 (no symptoms) to 3 (severe symptoms);, 2. Medication scores (MS), taking into account the exact number of anti-histamine tablets, nasal corticosteroid puffs, eye drops, 3. Rhino-conjunctivitis Quality of Life Questionnaire (RQLQ)

Interventions

DRUGSodium chloride 9mg/1000ml

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Symptom scores (SS) (primary endpoint), ranging from 0 to 18 points, with 3 nasal and 3 ocular symptoms (runny nose, blocked nose, sneezing, red eyes, itchy eyes and watery eyes), each of which scored from 0 (no symptoms) to 3 (severe symptoms);, 2. Medication scores (MS), taking into account the exact number of anti-histamine tablets, nasal corticosteroid puffs, eye drops, 3. Rhino-conjunctivitis Quality of Life Questionnaire (RQLQ)	—

Measure

Time frame

—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026